Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia(T-ALL)is one of the most dangerous hematological malignancies,with high tumor heterogeneity and poor prognosis.More than 60%of T-ALL patients carry NOTCH1 gene mutations,leading to abnormal expression of downstream target genes and aberrant activation of various signaling pathways.We found that chidamide,an HDAC inhibitor,exerts an antitumor effect on T-ALL cell lines and primary cells including an anti-NOTCH1 activity.In particular,chidamide inhibits the NOTCH1-MYC signaling axis by down-regulating the level of the intracellular form of NOTCH1(NICD1)as well as MYC,partly through their ubiquitination and degradation by the proteasome pathway.We also report here the preliminary results of our clinical trial supporting that a treatment by chidamide reduces minimal residual disease(MRD)in patients and is well tolerated.Our results highlight the effectiveness and safety of chidamide in the treatment of T-ALL patients,including those with NOTCH1 mutations and open the way to a new therapeutic strategy for these patients.

Histone variants:critical determinants in tumour heterogeneity

Malignant cell transformation could be considered as a series of cell reprogramming events driven by oncogenic transcription factors and upstream signalling pathways.Chromatin plasticity and dynamics are critical determinants in the control of cell reprograming.An increase in chromatin dynamics could therefore constitute an essential step in driving oncogenesis and in generating tumour cell heterogeneity,which is indispensable for the selection of aggressive properties,including the ability of cells to disseminate and acquire resistance to treatments.Histone supply and dosage,as well as histone variants,are the best-known regulators of chromatin dynamics.By facilitating cell reprogramming,histone under-dosage and histone variants should also be crucial in cell transformation and tumour metastasis.Here we summarize and discuss our knowledge of the role of histone supply and histone variants in chromatin dynamics and their ability to enhance oncogenic cell reprogramming and tumour heterogeneity.